-
Express Potential blockbuster gene therapy completes FDA marketing application submission
Time of Update: 2022-10-13
S. FDA its Biological Product Licensing Application (BLA) for its investigational gene therapy, valoctocogene roxaparvovec, for the treatment of adult patients with severe hemophilia A.
S. FDA its Biological Product Licensing Application (BLA) for its investigational gene therapy, valoctocogene roxaparvovec, for the treatment of adult patients with severe hemophilia A.
-
Sharing ASCT Academic Feast - CSCO Autologous Transplant Working Group 2022 Tour (Jiangxi & Fujian Station) was successfully held
Time of Update: 2022-10-13
, and the academic atmosphere was strong 。Professor Yi Kun of Jiangxi Provincial Cancer Hospital gave a report on the topic of "Clinical Application of PEG-rhG-CSF in Lymphoma Hematopoietic Stem Cell Transplantation".
-
2022CSH Race against the tide, precision treatment is just in time! ——Professor Ji Chunyan talked about the precise treatment of leukemia
Time of Update: 2022-10-13
Medical Pulse Pass: How do you think about the treatment status of domestic generic drugs and the current domestic application?Professor Ji ChunyanThe efficacy of the original drug is proven by rigorously designed long-term clinical studies and is reliable.
-
In 2022, CSH coffee gathered to talk about accurate diagnosis and treatment, and the 17th National Hematology Academic Conference of the Chinese Medical Association - Lymphocyte Disease was brilliant
Time of Update: 2022-10-13
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
2022CSH | Professor Chen Suning: New drugs and new technologies to promote the individualized diagnosis and treatment of AML
Time of Update: 2022-10-13
Could you please briefly introduce some of the new drug advances in the AML field?Professor Suning ChenThe treatment pattern of AML has undergone very significant changes since 2017, the continuous emergence of new drugs provides more treatment options for AML patients, and the new drugs that deserve attention mainly include the following categories: The first is the improvement of traditional cytotoxic drugs, such as CPX-351, mitoxantranone liposomes, etc.
-
Inflammatory anemia reviewed in the New England Journal of Medicine
Time of Update: 2022-10-13
Inflammatory anemia can be diagnosed when patients with n-cell-positive pigmented anemia have evidence of systemic inflammation (elevated erythrocyte sedimentation rate or C-reactive protein levels) and evidence of iron restriction due to nonsystemic iron deficiency (decreased transferrin saturation [100 micrograms/L]).
-
2022 CSH Professor Yi Shuhua: Cracking the treatment dilemma of mantle cell lymphoma, we are on the way
Time of Update: 2022-10-13
Listening to the sound of blood and perceiving the rhythm of life, on September 23-25, 2022, the "17th National Hematology Academic Conference of the Chinese Medical Association" was grandly opened at
-
2022 CSH Prof. Linghui Xia: Advances in the prevention and treatment of allogeneic hematopoietic stem cell transplantation in high-risk AML/MDS patients
Time of Update: 2022-10-13
At the conference, Professor Xia Linghui, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, introduced the current situation and prevention strategies of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) under the topic of "Progress in the Prevention and Control of Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk AML/MDS Patients".
-
2022CSH Professor Huang Liang: Based on the needs, the exploration continues, and the future development trend of double-strike and double-expression lymphoma diagnosis and treatment is expected according to the current status of diagnosis and treatment
Time of Update: 2022-10-13
Diffuse large B-cell lymphoma (DLBCL) has become one of the malignant tumors whose incidence is increasing year by year, and double-strike and double-expressed lymphoma belong to the special subtypes
-
2022CSH| Professor Jiang Erlie: Advances in the prevention and treatment of acute graft-versus-host disease
Time of Update: 2022-10-13
) to predict the risk of aGVHD, and has achieved preliminary results in adult and pediatric patients, especially in adult patients, the high risk of 23 days after transplantation can well predict the occurrence of aGVHD 。 Professor Jiang Erlie said that in the future, prospective clinical research will be carried out in this direction, using the system to predict the risk of aGVHD in patients, and intervening in high-risk patients before the emergence of aGVHD to better prevent aGVHD.
-
2022 CSH Prof. Wei Xu: An Exploration of CLL Diagnosis and Treatment Models in the Era of New Drugs
Time of Update: 2022-10-13
In addition, the choice of CLL treatment options is more abundant, although traditional immunochemotherapy is effective for some CLL patients, but for patients with del17p/TP53 mutation, IGHV unmutated, del (11q) and other high-risk factors are not effective, it is difficult to overcome the bad prognosis of such people, and the emergence of new drugs such as BTK inhibitors, BCL2 inhibitors, etc.
-
2022CSH Professor Qiu Lugui: Grasp the basics, pay attention to the progress, China's lymphoma treatment prospects are broad
Time of Update: 2022-10-13
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" will be grandly opened on Sept
-
2022CSH | Professor Han Weidong: Review and prospect of CAR-T cells in the treatment of hematologic malignancies
Time of Update: 2022-10-13
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
2022CSH Prof. Hui Wei: Progress in the treatment of acute myeloid leukemia with FLT3 mutation
Time of Update: 2022-10-13
The 17th National Hematology Academic Conference of the Chinese Medical Association was grandly opened in Shanghai on September 23-25, 2022, with the theme of "respect, inheritance, collaboration and
-
2022CSH| Professor Qingqing Cai: Progress in the treatment of NK/T-cell lymphoma
Time of Update: 2022-10-13
PD-1 monoclonal antibody combined with P-GemOx immunochemotherapy has also achieved good efficacy in advanced NK/T-cell lymphoma, and the side effects are controllable, which can be used as a new treatment option for patients with NK/T-cell lymphoma.
-
Viruses-Basel: Long-term outcomes after vaccine-induced thrombotic thrombocytopenia
Time of Update: 2022-10-12
The blue line represents the D-dimer (left axis, linear, reference value 4 times the upper limit of normal.
The blue line represents the D-dimer (left axis, linear, reference value 4 times the upper limit of normal.
-
Blood: MRD dynamics during maintenance therapy help improve prognosis
Time of Update: 2022-10-12
Progression-free survival of patients with different MRD states at the time of 14-month analysisIn patients with MRD+ at randomized grouping, Ixazomib maintenance therapy prolonged PFS compared to placebo (median PFS: 18.
-
Leukemia: Professor Ji Chunyan's team revealed a new target for the treatment of acute T lymphoblastic leukemia
Time of Update: 2022-10-12
Recently, the team of Professor Ji Chunyan from the Department of Hematology of Qilu Hospital of Shandong University, the team of Professor Li Jingxin from the School of Basic Medicine of Shandong University, and the team of Professor Baobing Zhao from the School of Pharmacy of Shandong University jointly published the title "Inhibition of the m6A Reader IGF2BP2 as a Strategy against Leukemia, an authoritative journal in the field of hematology and tumor.
-
Int Urol Nephrol : A study of the relationship between PCPE-1 and renal function in patients with multiple myeloma
Time of Update: 2022-10-12
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
PCPE-1 levels were not affected by other parameters throughout the study population and the MM group.
-
Leukemia: Professor Ji Chunyan's team revealed a new target for the treatment of acute T lymphoblastic leukemia
Time of Update: 2022-10-12
Recently, the team of Professor Ji Chunyan from the Department of Hematology of Qilu Hospital of Shandong University, the team of Professor Li Jingxin from the School of Basic Medicine of Shandong University, and the team of Professor Baobing Zhao from the School of Pharmacy of Shandong University jointly published the title "Inhibition of the m6A Reader IGF2BP2 as a Strategy against Leukemia, an authoritative journal in the field of hematology and tumor.
